Drug Pipeline Insights Report
3 new first-in-class therapies coming
See how innovation is driving the latest product development.
By Sumit Dutta, MD, Chief Medical Officer at Optum Rx | Published: April 2023
2023 will be a busy year for new pharmaceutical treatments.
Welcome to the next issue of Drugs to Watch for 2023
In this Drug Pipeline Insights Report, we review:
- Two respiratory syncytial virus (RSV) vaccines
- A gene therapy for Duchenne muscular dystrophy (DMD)
- First FDA-approved treatment for nonalcoholic steatohepatitis (NASH), a rare liver disease
Don't want to read the full report? Download the brief summary.
Related Content
4 new drugs to watch this year
Breakthrough treatments for menopause, Alzheimer's and hemophilia are coming.
Which rules will impact pharmacy in 2023?
2023 is already a busy year for pharmacy regulation. Read about the latest regulations that could impact you and your pharmacy benefit plan.
3 new drugs to watch this fall
As the year begins to close, we highlight three essential pipeline drugs with an expected U.S. Food and Drug Administration (FDA) decision this fall.
Top